The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study.

Deniz Can GuvenMusa Baris AykanHarun MugluErtugrul BayramKaan HelvaciBengü DursunMelisa CelayirElvin ChelebiyevErdinc NayirMustafa ErmanAhmet SezerYuksel UrunUmut DemirciOzlem ErUmut DiselAhmet BiliciCagatay ArslanNuri Karadurmus Saadettin Kılıçkap

Published in: Cancer medicine (2023)

We observed over 30% ORR and a 13-month median OS in patients with rare cancers treated with ICI monotherapy or ICI plus CT combinations. The response rates to ICIs or ICIs plus CT significantly varied across different tumor types. Responding patients had over 2 years of survival, highlighting a need for further trials with ICIs for patients with rare tumors.

Keyphrases

end stage renal disease
computed tomography
newly diagnosed
image quality
ejection fraction
chronic kidney disease
dual energy
prognostic factors
palliative care
positron emission tomography
clinical trial
magnetic resonance
open label
patient reported
study protocol